Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
Tongji University · Shanghai Pulmonary Hospital · +42 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
120
total citations
- FWCI
- 94.23
- Percentile
- 100%
- References
- 22
Citations per year
Authors
45- AXAnwen XiongCorresponding
Tongji University, Shanghai Pulmonary Hospital
- LWLei Wang
Tongji University, Shanghai Pulmonary Hospital
- JCJianhua Chen
Hunan Cancer Hospital, Fujian Provincial Cancer Hospital
- LWLin Wu
Hunan Cancer Hospital
- BLBaogang Liu
Harbin Medical University, Third Affiliated Hospital of Harbin Medical University
Topics & keywords
Topics
Keywords
- Pembrolizumab
- Medicine
- Double blind
- Internal medicine
- Oncology
- Lung cancer
- PD-L1
- Cancer
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.